Valeant Pharmaceuticals International, Inc. (VRX) Raised to “Buy” at TD Securities

TD Securities upgraded shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) from a hold rating to a buy rating in a report published on Friday, November 3rd. The firm currently has $20.00 target price on the specialty pharmaceutical company’s stock.

A number of other equities research analysts have also recently commented on VRX. J P Morgan Chase & Co reissued a neutral rating and issued a $10.00 price objective on shares of Valeant Pharmaceuticals International in a research note on Thursday, July 6th. Zacks Investment Research downgraded shares of Valeant Pharmaceuticals International from a hold rating to a strong sell rating in a research report on Thursday, July 13th. Piper Jaffray Companies reissued an underweight rating and set a $10.00 target price on shares of Valeant Pharmaceuticals International in a research report on Friday, July 14th. Wells Fargo & Company reissued a sell rating on shares of Valeant Pharmaceuticals International in a research report on Friday, July 14th. Finally, Jefferies Group LLC reaffirmed a buy rating and issued a $18.00 price objective on shares of Valeant Pharmaceuticals International in a research report on Friday, July 14th. Five equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of Hold and a consensus price target of $17.17.

Shares of Valeant Pharmaceuticals International (VRX) traded up $0.55 on Friday, reaching $16.54. 21,460,634 shares of the company’s stock traded hands, compared to its average volume of 17,934,104. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 4.84. Valeant Pharmaceuticals International has a 12 month low of $8.31 and a 12 month high of $18.25. The firm has a market cap of $5,750.00, a PE ratio of 2.53, a P/E/G ratio of 0.43 and a beta of -0.40.

TRADEMARK VIOLATION NOTICE: “Valeant Pharmaceuticals International, Inc. (VRX) Raised to “Buy” at TD Securities” was published by BBNS and is the property of of BBNS. If you are accessing this report on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this report can be accessed at https://baseballnewssource.com/markets/valeant-pharmaceuticals-international-inc-vrx-given-hold-rating-at-td-securities/1755050.html.

In other Valeant Pharmaceuticals International news, Director John Paulson purchased 344,216 shares of the stock in a transaction on Thursday, November 16th. The stock was bought at an average cost of $14.40 per share, for a total transaction of $4,956,710.40. Following the completion of the acquisition, the director now directly owns 94,559 shares of the company’s stock, valued at $1,361,649.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 5.87% of the stock is owned by corporate insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in VRX. Sumitomo Mitsui Trust Holdings Inc. lifted its holdings in Valeant Pharmaceuticals International by 2.9% during the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 490,395 shares of the specialty pharmaceutical company’s stock worth $8,509,000 after purchasing an additional 13,810 shares during the last quarter. Legal & General Group Plc increased its stake in shares of Valeant Pharmaceuticals International by 9.2% in the 2nd quarter. Legal & General Group Plc now owns 1,435,670 shares of the specialty pharmaceutical company’s stock valued at $23,895,000 after purchasing an additional 121,032 shares during the last quarter. Paloma Partners Management Co grew its position in Valeant Pharmaceuticals International by 12.0% during the 1st quarter. Paloma Partners Management Co now owns 27,996 shares of the specialty pharmaceutical company’s stock worth $310,000 after acquiring an additional 2,996 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Valeant Pharmaceuticals International by 9.8% during the 1st quarter. Vanguard Group Inc. now owns 6,980,074 shares of the specialty pharmaceutical company’s stock worth $76,990,000 after buying an additional 621,618 shares during the period. Finally, Shell Asset Management Co. lifted its holdings in Valeant Pharmaceuticals International by 197.5% during the 3rd quarter. Shell Asset Management Co. now owns 92,128 shares of the specialty pharmaceutical company’s stock worth $13,407,000 after buying an additional 61,157 shares during the period. 48.49% of the stock is owned by institutional investors.

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot
Angels Sign Former Prospect with Braves Kevin Maitan
Angels Sign Former Prospect with Braves Kevin Maitan
Shohei Ohtani Has Turned Down Red Sox and Yankees
Shohei Ohtani Has Turned Down Red Sox and Yankees
Free Agency Season Has Finally Heated Up
Free Agency Season Has Finally Heated Up


Leave a Reply

 
© 2006-2017 BBNS.